Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine.

Renee C Prins, M.D., Russell T Burke, Marc M Loriaux, MD, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 2471.

https://doi.org/10.1182/blood.V120.21.2471.2471

Published: 2012

Journal Articles

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

Marie O'Farrell, PhD, Richard Ventura, Albert Tai, Jeffrey W Tyner, PhD, Marc M Loriaux, MD, PhD, Daruka Mahadevan, MD, PhD, Carla Morales, S. David Brown, David J Matthews, PhD

Blood (2012) 120 (21): 2907.

https://doi.org/10.1182/blood.V120.21.2907.2907

Published: 2012

Journal Articles

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

Russell T Burke, Astrid Clarke, Sarah A Meadows, Marc M Loriaux, MD, PhD, Jennifer B Dunlap, MD, Guang Fan, MD, PhD, Patricia Maciejewski, Julie Di Paolo, Brian J. Lannutti, PhD, Brian J. Druker, Stephen E Spurgeon, MD

Blood (2012) 120 (21): 3876.

https://doi.org/10.1182/blood.V120.21.3876.3876

Published: 2012

Journal Articles

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

Julia E Maxson, PhD, Jason Gotlib, Angela G. Fleischman, MD, PhD, Christopher A. Eide, Daniel Bottomly, MS, Beth Wilmot, PhD, MS, Shannon McWeeney, PhD, Cristina Tognon, PhD, Marc M Loriaux, MD, PhD, Brian J. Druker, Jeffrey W Tyner, PhD

Blood (2012) 120 (21): 2412.

https://doi.org/10.1182/blood.V120.21.2412.2412

Published: 2012

Journal Articles

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

Qian Yu, BS, Anna M Eiring, PhD, Matthew S. Zabriskie, Jamshid Khorashad, MD, PhD, David J Anderson, BS, Jade A Bryant, BS, Marc M Loriaux, MD, PhD, Jeffrey W Tyner, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 2481.

https://doi.org/10.1182/blood.V118.21.2481.2481

Published: 2011

Journal Articles

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

Renee C Prins, M.D., Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Luke B Fletcher, Abdusebur Jemal, Jade A Bryant, BS, Russell T Burke, Bill H Chang, MD, PhD, Tibor Kovacsovics, MD, Brian J. Druker, Marc M Loriaux, MD, PhD

Blood (2011) 118 (21): 3512.

https://doi.org/10.1182/blood.V118.21.3512.3512

Published: 2011

Journal Articles

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

Stephen Spurgeon, MD, Luke B Fletcher, Jeffrey W Tyner, PhD, Brian J Druker, MD, Anjali Pandey, PhD, Uma Sinha, PhD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2839.

https://doi.org/10.1182/blood.V116.21.2839.2839

Published: 2010

Journal Articles

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Jeffrey W Tyner, PhD, Stephen Spurgeon, MD, Luke B Fletcher, Wayne Yang, Tibor Kovacsovics, MD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2754.

https://doi.org/10.1182/blood.V116.21.2754.2754

Published: 2010

Journal Articles

Effects of Plerixafor (AMD3100) In Combination with Tyrosine Kinase Inhibition In a Murine Model of CML.

Anupriya Agarwal, PhD, Angela G. Fleischman, MD, PhD, Curtis L Petersen, Marc M Loriaux, MD, PhD, Randy Woltjer, Brian J Druker, MD, Michael W Deininger, MD, PhD

Blood (2010) 116 (21): 3389.

https://doi.org/10.1182/blood.V116.21.3389.3389

Published: 2010

Journal Articles

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Stephen Spurgeon, MD, Talia Pindyck, MD, Marc M Loriaux, MD, PhD, Craig Okada, MD, PhD, Kamal Abbi, Yiyi Chen, Zunqui Chen, Elana Mater, Elliott Epner, MD, PhD

Blood (2010) 116 (21): 4910.

https://doi.org/10.1182/blood.V116.21.4910.4910

Published: 2010

Journal Articles

p27 Is Mislocalized to the Cytoplasm by BCR-ABL In a Kinase-Independent Manner and Contributes to Leukemogenesis

Anupriya Agarwal, PhD, Ryan J Meckenzie, Thomas O'Hare, PhD, Kavin B Vasudevan, Dorian H LaTocha, Marc M Loriaux, MD, PhD, Eduardo Firpo, James M Roberts, Brian J Druker, MD, Michael W Deininger, MD, PhD

Blood (2010) 116 (21): 512.

https://doi.org/10.1182/blood.V116.21.512.512

Published: 2010

Journal Articles

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Luke B Fletcher, Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 3594.

https://doi.org/10.1182/blood.V116.21.3594.3594

Published: 2010

Journal Articles

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Jeffrey W Tyner, PhD, Paul Tardi, PhD, Lawrence Mayer, PhD, Luke B Fletcher, Stephen Spurgeon, MD, Tibor Kovacsovics, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2886.

https://doi.org/10.1182/blood.V116.21.2886.2886

Published: 2010

NARROW

CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine.

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3Kδ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973

A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Effects of Plerixafor (AMD3100) In Combination with Tyrosine Kinase Inhibition In a Murine Model of CML.

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

p27 Is Mislocalized to the Cytoplasm by BCR-ABL In a Kinase-Independent Manner and Contributes to Leukemogenesis

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only